FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,879,836 | -38.0% | 886,715 | +39.2% | 0.00% | 0.0% |
| Q2 2023 | $3,031,087 | -14.1% | 636,783 | +2.9% | 0.00% | 0.0% |
| Q1 2023 | $3,527,360 | -43.1% | 618,835 | +0.7% | 0.00% | -50.0% |
| Q4 2022 | $6,201,647 | -54.0% | 614,633 | +2.2% | 0.00% | -60.0% |
| Q3 2022 | $13,480,000 | -33.8% | 601,478 | -26.8% | 0.01% | -28.6% |
| Q2 2022 | $20,369,000 | -35.6% | 821,983 | +0.8% | 0.01% | -22.2% |
| Q1 2022 | $31,613,000 | -32.0% | 815,382 | +2.6% | 0.01% | -35.7% |
| Q4 2021 | $46,499,000 | +0.9% | 794,708 | +2.2% | 0.01% | -6.7% |
| Q3 2021 | $46,073,000 | -9.0% | 777,327 | +33.3% | 0.02% | -11.8% |
| Q2 2021 | $50,611,000 | +8.8% | 583,138 | +3.3% | 0.02% | 0.0% |
| Q1 2021 | $46,530,000 | +6.5% | 564,342 | +17.5% | 0.02% | 0.0% |
| Q4 2020 | $43,686,000 | +130.5% | 480,428 | +1.3% | 0.02% | +88.9% |
| Q3 2020 | $18,950,000 | +24.3% | 474,087 | +6.7% | 0.01% | +28.6% |
| Q2 2020 | $15,243,000 | +78.1% | 444,272 | +15.3% | 0.01% | +40.0% |
| Q1 2020 | $8,560,000 | +15.0% | 385,406 | +1.4% | 0.01% | +25.0% |
| Q4 2019 | $7,441,000 | +40.3% | 380,212 | +11.4% | 0.00% | +33.3% |
| Q3 2019 | $5,303,000 | +100.0% | 341,409 | +161.5% | 0.00% | +50.0% |
| Q2 2019 | $2,651,000 | +4.5% | 130,573 | -9.5% | 0.00% | 0.0% |
| Q1 2019 | $2,536,000 | +42.6% | 144,332 | +4.2% | 0.00% | +100.0% |
| Q4 2018 | $1,778,000 | -1.7% | 138,538 | +24.9% | 0.00% | 0.0% |
| Q3 2018 | $1,808,000 | +51.3% | 110,960 | +5.4% | 0.00% | 0.0% |
| Q2 2018 | $1,195,000 | +25.5% | 105,300 | +8.0% | 0.00% | 0.0% |
| Q1 2018 | $952,000 | +135.6% | 97,500 | +47.7% | 0.00% | – |
| Q4 2017 | $404,000 | +54.2% | 66,000 | 0.0% | 0.00% | – |
| Q3 2017 | $262,000 | +22.4% | 66,000 | 0.0% | 0.00% | – |
| Q2 2017 | $214,000 | – | 66,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |